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Abstract 
  BACKGROUND: This study aimed to evaluate the effects of streptokinase on left ventricular 
ejection fraction and mortality rate of patients with inferior acute myocardial infarction (AMI) 
without right ventricular myocardial infarction (RVMI). 
 METHODS:  Fifty five consecutive patients with the diagnosis of inferior AMI without RVMI in 
the coronary care unit (CCU) of Shariati Hospita l  i n  I s f a h a n  w e r e  s e l e c t e d  f o r  t h i s  s t u d y .  
Patients who had a history and/or electrocardiogram (ECG) evidence of previous myocardial 
infarction, evidence of bundle branch block, historical or clinical findings of valvular or other 
non-coronary heart diseases or heart failure were excluded. Participants were divided into two 
groups. Group one (n = 28) had no contraindication for taking thrombolytic therapy and group 
two (n = 27) had at least one contraindication for this treatment. Patients in group one took 
1,000,000 units streptokinase for one hour. Three days later, LVEF of all participants was 
measured by an experienced cardiologist using 2-dimentiona1 echocardiography. Patients were 
followed up until four weeks to assess the mortality rate. 
 RESULTS: One death in the first 24 hours was reported in group one. However, no death was 
reported in any group until four weeks after discharge. There was no significant difference in 
mortality rate during the first 24 hours and four weeks after discharge between the two groups. 
Mean LVEF in the two groups did not show any significant difference (P = 0.21). 
  CONCLUSION: Probably streptokinase has no effects on one-month mortality rate and LVEF in 
patients with inferior AMI without RVMI. Therefore, streptokinase side effects must be taken 
into consideration when being administered for this group of patients. 
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Introduction 
Thrombolysis is claimed to be the treatment of choice 
for patients with acute myocardial infarction (AMI) 
less than 12 hours in duration who present ST 
segment elevations on their admission 
electrocardiogram (ECG), irrespective of the site of 
AMI.1,2 
  The risk to benefit ratio of thrombolytic therapy in 
patients with inferior AMI continues to be 
controversial.3-6 It has been suggested that only 
patients with inferior AMI presenting larger ST 
segment deviations would benefit from thrombolytic 
therapy.7 In addition, the effects of thrombolytic 
therapy on left ventricular ejection fraction (LVEF) 
have been small and inconsistent.7-9 
  Although hemorrhagic stroke is a rare and 
serious complication of thrombolytic therapy, if a 
patient has had a history of thrombolytic therapy 
before, an allergy against the thrombolytic agent may 
have developed. These two side effects of 
thrombolysis are worsened using streptokinase.10-12 
  In Iran, the most available thrombolytic agent 
used is streptokinase. Therefore, according to the 
side effects of this drug, we designed this study to 
assess streptokinase effects on LVEF and mortality 
rate in patients with inferior AMI without right 
ventricular myocardial infarction (RVMI). 
Materials and Methods 
This cross-sectional study was approved by the Ethics 
Committee of Islamic Azad University of Najaf Abad
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. In addition, all participants signed an informed 
consent. 
  Samples were selected from patients admitted in 
the coronary care unit (CCU) of Shariati Hospital in 
Isfahan, during September 23-March 19, 2008, 
diagnosed with inferior AMI without RVMI. 
Sampling method was convenient. 
  The diagnosis of inferior AMI without RVMI 
criteria included9,13,14 chest pain or discomfort 
compatible with myocardial ischemia lasting longer 
than one hour, an elevation of 0.1 mV or more of 
the ST segment in three inferior leads (II, III, aVF) 
documented in the ECG within 4 hours of the onset 
of the symptoms, an elevation of serum creatinine 
phosphokinase (CPK) to 125% or more of the upper 
limit of the respective laboratory associated with the 
presence of MB-CPK, an ST segment elevation of 
0.1 mV or more in the right precordial chest lead 
without V4R. 
  Patients were excluded if one of these items were 
present: historical or ECG evidence of previous 
myocardial infarction, evidence of bundle branch 
block, or historical or clinical findings of valvular 
heart disease or heart failure. 
  Finally, 55 patients were selected and divided into 
two groups. Patients in group one (n = 28) had no 
contraindication for thrombolytic therapy and 
patients in group two (n = 27) had at least one 
contraindication for taking thrombolytic agent. 
  The patients’ weight and height were measured 
while they were barefoot wearing light indoor 
clothing. Body mass index (BMI) was then calculated 
for each subject as weight (kg) divided by height 
squared (m2). 
  Systolic blood pressure (SBP) and diastolic blood 
pressure (DBP) were measured twice with 5 minutes 
intervals using a standard mercury 
sphygmomanometer in a quiet and comfortable room. 
  Patients’ blood samples were taken after 12 hours 
of fasting for measuring total cholesterol (TC), 
triglyceride (TG), high-density lipoprotein (HDL-C), 
low density lipoprotein (LDL-C), and fasting blood 
sugar (FBS). 
  Patients were considered hypertensive if they had 
a history of high blood pressure and/or were using 
any anti-hypertensive drugs, and/or SBP ≥ 140 
mmHg. Dyslipidemic patients were defined as having 
a history of dyslipidemia and/or TC ≥ 200 and/or 
TG ≥ 150 and/or LDL-C ≥ 100 and/or HDL-C ≤ 40 
in males and ≤ 50 in females. Patients with FBS ≥ 126, 
and/or a history of diabetes mellitus, and/or taking 
anti-diabetic drugs were considered diabetic. 
  The contraindications for taking thrombolytic 
agent included a history of cerebrovascular 
hemorrhage at any time, a non-hemorrhagic stroke 
or another cerebrovascular event within the past 
year, SBP > 180 mmHg and/or DBP ≥ 110 mmHg 
at any time during the acute presentation, suspicion 
of aortic dissection, and active internal bleeding 
except for menses.10  
  Aspirin and intravenous heparin were 
administered to all patients. Other medications, 
including nitrates and calcium channel blockers, were 
used if considered necessary after the clinical 
examination by the physician. In addition, 1,000,000 
units streptokinase during a one-hour period was 
ordered only for group one. An experienced 
cardiologist measured LVEF of patients using a 2-
dimentional echocardiography 3 days after AMI. 
  In order to evaluate the mortality rate, the patients 
were followed up every week by phone until four 
weeks after discharge. Data were analyzed using SPSS 
version 13 and independent t-test was used to 
compare the two groups' data. P-value less than 0.05 
was considered as statistically significant. 
Results 
As Table 1, including patients' physical and 
demographic data, shows, there were not any 
significant differences between the two groups.  
  Only one patient died in group one in the first 24 
hours and no death was recorded during the 4 weeks 
after discharge in both groups. There was not a 
significant difference between the two groups in 
mortality rate at the first 24 hours (P = 0.51) and 4 
weeks after discharge (P = 0.43).  
  Mean ejection fraction was 46.96 + 11.96% in 
group one and 51.11 + 12.58% in group two. 
Although ejection fraction in group one was 1.08 
times more than group two, the difference was not 
significant (P = 0.21). 
Discussion 
Present study findings showed that mortality rate and 
LVEF of patients with acute inferior myocardial 
infarction without RVMI who took streptokinase is 
not higher than those who did not take this 
medication. 
  Despite more than a decade of extensive clinical 
trials, the use of thrombolytic treatment in patients 
with inferior wall AMI continues to be 
controversial.1,4,12 Some studies have claimed that 
thrombolytic treatment should be given to all patients 
presenting an ST segment elevation.13 Although the 
results are less convincing in patients with inferior 
AMI, treatment may save tens of thousands of lives 
worldwide each year.1,2 
Borgia et al. concluded that thrombolytic therapy in 
patients with inferior AMI would improve the 
www.mui.ac.ir ISOLATED ACUTE INFERIOR MYOCARDIAL INFARCTION, EJECTION FRACTION AND MORTALITY RATE 
56  ARYA Atherosclerosis Journal 2011 (Summer); Volume 7, Issue 2   
Table 1. Demographic and physical characteristics of patients in the two groups 
P-value  Group two 
N = 27 
Group one 
N = 28  Data 
0.49  61.88 + 16.16  59.48 + 13.05  Age (mean ± SD) 
0.88  25.53 + 2.4  25.44 + 1.9  BMI (mean ± SD) 
0.09  60.9%  39.1%  DM 
0.30  54.2%  45.8%  HTN 
0.14  36.8%  63.2%  DLP 
BMI = body mass index; DM = diabetes mellitus; HTN = hypertension; DLP = dyslipidemia. 
 
patients’ prognosis (ST segment depression persisting 
for more than 24 hours) to a better prognosis (ST 
segment depression persisting for less than 24 
hours).12 Another study with the same aim showed 
that thrombolytic therapy in patients with inferior 
AMI presenting larger ST segment deviations is 
associated with improved 6-year survival rates.10  
  However, the risk to benefit ratio, in terms of early 
mortality in patients who have an ST of 0.smr or less 
no pericardial ST segment depression may be 
unfavorable.9 In Iran, a study evaluating the role of 
thrombolytic therapy in inferior AMI with RVMI 
found LVEF in patients who received streptokinase 
decreased less than patient who did not receive 
streptokinase.12  
  In our study, there was no significant difference in 
ST segment depression in precordial leads between 
the two groups. Moreover, patients had no RVMI and 
their age, sex, history of diabetes mellitus, 
hypertension, dyslipidemia, smoking and addiction 
were matched. We found no significant differences in 
the mortality rate during the first 24 hours and one 
month after discharge between the two groups. This 
result is in agreement with a study conducted by 
Robalino, et al.13 but our sample size was small. In 
addition, in this study ST segment depression was not 
significantly different between the two groups and we 
did not evaluate the effects of thrombolytic therapy 
on patients with RVMI.  
  Generally, this study shows that streptokinase has 
no effect on LVEF and mortality rate in the first 24 
hours and one month after discharge. Considering 
that streptokinase is the only available thrombolytic 
agent in our country, the drug’s side effects must be 
considered for administration in patients with inferior 
AMI without RVMI. 
  We suggest a study with a larger sample size for 
comparing the effects of streptokinase in patients 
with inferior AMI with or without RVMI. 
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